Synthetic Biology Firm Synthorx Launches | GenomeWeb

NEW YORK (GenomeWeb) – Synthetic biology firm Synthorx launched today with exclusive rights to a technology developed by a researcher at the Scripps Research Institute.

Based in San Diego, Synthorx also has received an investment from Avalon Ventures and Correlation Ventures, though it didn't disclose the amount of the funding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.